Interstitial Cystitis - Few Treatments, Poor Outcome

Interstitial cystitis (IC) is considered a rare disorder and poor understanding of the underlying causes of the disorder have made diagnosis and management difficult. Moreover, this has impacted on the development of effective drugs for this disorderthere are few available treatments for IC and as a result, significant unmet needs exist.

Scope

Quantitative treatment data from 190 physicians based in US, Japan, France, Germany, Italy, Spain and UK; supported by key opinion leader comments

Analysis of epidemiology, presentation and referral patterns, diagnostic assessment, and first- to second-line treatments for IC

Influences on treatment choice and perception of current drug therapies including pentosan polysulfate sodium and the antimuscarinics

Influences on treatment choice and perception of current drug therapies, unmet needs and future outlook including the R&D drug pipeline

Highlights

Presentation rates for IC are higher than in other OAB disorders due to the patient experience of pain. However, discord in the terminology and diagnostic criteria for IC confound diagnosis; and as result, the diagnosis of IC tends to be one of exclusion, and as such can take many years to be reached, bringing unnecessary suffering to the patient.

IC symptoms have a similar terminology to those of Overactive Bladder, but are fundamentally different. Poor understanding of the disorder and limited treatment options means that many physicians have resorted to using antimuscarinics despite their limited proven efficacy in treating the pain.

Further research into the etiology of IC is the key to finding a truly effective treatment for IC that works. In the meantime, companies wishing to target the IC market should aim to demonstrate the ability of their drug to treat pain in addition to urgency and frequency.

Reasons to Purchase

Forecast product sales by understanding key aspects of IC epidemiology, diagnosis and treatment

Gain a better understanding of the challenges facing current and future players in the IC market

Identify physicians key concerns in IC including unmet needs and the attributes that physicians believe are desirable for future treatments

14-Apr-06 Slide Pack Pages/Slides 50

Table of Contents
Price: $7,600.00 / GBP3,800.00